Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Legend Biotech Corp (LEGN US)
Watchlist
94
Analysis
Health Care
•
China
Legend Biotech Corporation operates as a biopharmaceutical company. The Company engages in discovery and development of novel cell therapies for oncology and other indications. Legend Biotech serves customers in the State of New Jersey.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Legend Biotech Corp
•
26 Jul 2022 11:44
Legend Biotech Follow-On - A Little Opportunistic. Last Deal Did Well, After a Large Correction
Legend Biotech Corp (LEGN US), a non-wholly owned subsidiary of Hong Kong-listed Genscript Biotech (1548 HK), is planning to raise up to US$250m in...
Sumeet Singh
Follow
305 Views
Share
bullish
•
Genscript Biotech
•
31 May 2022 09:06
Genscript Biotech - Commercialized CAR-T & Strong CGT CDMO Indicate Exponential Growth in Valuation
GenScript’s commercialization of CAR-T, rapid growing GCT CDMO and “all-in” on GCT industry chain indicate exponential growth potential in...
Xinyao (Criss) Wang
Follow
334 Views
Share
bearish
•
Thematic (Sector/Industry)
•
29 May 2022 09:11
China Healthcare Weekly (May.27) - New TAVR Policy, Exiting Issue of COVID Testing, RemeGen/Keymed
New TAVR policy will break the low demand bottleneck due to high cost; COVID testing industry faces the problem of exit; Remegen/Keymed may have...
Xinyao (Criss) Wang
Follow
340 Views
Share
bullish
•
Thematic (Sector/Industry)
•
08 May 2022 09:03
China Healthcare Weekly (May.6)-FDA’s CRL on Junshi/HCM, Biotech Globalization, Significance of DRGs
The FDA announced its CRL on Hutchmed’s surufatinib and Junshi’s PD-1. It's time to reexamine the logic and prospects of biotech globalization. The...
Xinyao (Criss) Wang
Follow
272 Views
Share
bullish
•
Legend Biotech Corp
•
17 Apr 2022 17:51
Legend Biotech Corp (LEGN US): Carvykti Approval Is the Silver Lining Amid Uncertainty of Delisting
FDA approval of the company’s first drug Carvykti, with initial peak sales opportunity of $1.5 billion should be considered as a buy opportunity,...
Tina Banerjee
Follow
803 Views
Share
First
Previous
7
8
9
10
11
12
13
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.5
x